Want to see GDRX full AI Analyst Report?
GDRX Stock Chart & Stats
$2.27
-$0.12(-2.72%)
At close: 4:00 PM EST
$2.27
-$0.12(-2.72%)
Day’s Range― - ―
52-Week Range$1.77 - $5.81
Previous CloseN/A
Volume261.88K
Average Volume (3M)1.11M
Market Cap
$1.06B
Enterprise Value$974.83
Total Cash (Recent Filing)$235.71M
Total Debt (Recent Filing)$541.35M
Price to Earnings (P/E)53.6
Beta0.84
Next Earnings
Aug 05, 2026EPS Estimate
0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding104,711,190
10 Day Avg. Volume765,056
30 Day Avg. Volume1,114,748
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)1.57
Price to Sales (P/S)1.21
P/FCF Ratio5.87
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$3.60Price Target Upside58.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)0.31
Revenue Forecast (FY)$775.88M
Bulls Say, Bears Say
Bulls Say
Balance-sheet StrengthMaterial de-leveraging to ~0.09–0.10 on TTM balance-sheet metrics meaningfully lowers financial risk and increases strategic flexibility. This durable improvement supports disciplined reinvestment, M&A optionality, and resilience to cyclical stress without pressuring cash flows or margins.
Free Cash Flow GenerationConsistent positive operating and free cash flow with >20% TTM FCF growth underpins self-funded growth and reinvestment in strategic initiatives. Durable cash generation reduces reliance on external capital, supports margin stability, and enables sustained investment in Pharma Direct and subscription expansion.
Strategic Revenue DiversificationRapid Pharma Direct expansion and higher-growth subscription programs shift revenue away from legacy PTR. This structural diversification captures manufacturer demand and creates higher-margin, recurring relationships with brands and pharmacies, improving long-term revenue durability and strategic positioning.
Bears Say
Legacy Prescription Revenue DeclineA 24% YoY decline in core prescription transactions shrinks the historical revenue base and reduces scale benefits tied to marketplace volume. Sustained PTR erosion pressures overall top-line growth, weakens legacy fee streams, and forces reliance on newer initiatives to offset lost transactional cash flow.
Stagnant User Growth (MAC)Flat monthly active consumers indicates limited audience expansion, constraining long-term prescription and advertising volume growth. Without durable MAC growth, scaling higher-margin programs and improving monetization per user becomes harder, exposing revenue to unit-economic shifts rather than organic reach gains.
Mix Shift And Unit-economics PressureMoving revenue mix toward Pharma Direct and subscriptions alters per-transaction economics and can lower unit margins. Over the medium term, this raises execution risk: the business must scale newer programs enough to offset lower unit economics while managing pricing volatility in GLP-1s and competitive/regulatory pressure on manufacturer-funded programs.
GoodRx Holdings News
GDRX FAQ
What was Goodrx Holdings, Inc.’s price range in the past 12 months?
Goodrx Holdings, Inc. lowest stock price was $1.77 and its highest was $5.81 in the past 12 months.
What is Goodrx Holdings, Inc.’s market cap?
Goodrx Holdings, Inc.’s market cap is $1.06B.
When is Goodrx Holdings, Inc.’s upcoming earnings report date?
Goodrx Holdings, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 18 days.
How were Goodrx Holdings, Inc.’s earnings last quarter?
Goodrx Holdings, Inc. released its earnings results on May 06, 2026. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.072 by -$0.002.
Is Goodrx Holdings, Inc. overvalued?
According to Wall Street analysts Goodrx Holdings, Inc.’s price is currently Undervalued.
Does Goodrx Holdings, Inc. pay dividends?
Goodrx Holdings, Inc. does not currently pay dividends.
What is Goodrx Holdings, Inc.’s EPS estimate?
Goodrx Holdings, Inc.’s EPS estimate is 0.08.
How many shares outstanding does Goodrx Holdings, Inc. have?
Goodrx Holdings, Inc. has 104,711,190 shares outstanding.
What happened to Goodrx Holdings, Inc.’s price movement after its last earnings report?
Goodrx Holdings, Inc. reported an EPS of $0.07 in its last earnings report, missing expectations of $0.072. Following the earnings report the stock price went up 10.506%.
Which hedge fund is a major shareholder of Goodrx Holdings, Inc.?
Currently, no hedge funds are holding shares in GDRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GoodRx Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.60 (58.59% Upside)
$3.60 (58.59% Upside)
Blogger Sentiment
Bullish
GDRX Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 287.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.2%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-34.45%
12-Months-Change
Fundamentals
Return on Equity
3.31%
Trailing 12-Months
Asset Growth
56.05%
Trailing 12-Months
Company Description
Goodrx Holdings, Inc.
GoodRx Holdings, Inc. provides American consumers with essential resources and tools to compare and ultimately lower the cost of their prescription medications. The company operates a digital platform dedicated to price comparison, delivering customized, geographically tailored prescription pricing. It also grants access to special, negotiated rates through unique GoodRx codes, which can be utilized for savings on prescriptions throughout the entire United States. Beyond this core offering, the firm also extends its portfolio to include subscription services, programs designed for pharmaceutical manufacturers, and telehealth capabilities. GoodRx additionally collaborates with pharmacy benefit managers, entities responsible for managing drug formularies and overseeing prescription transactions, including the critical task of setting prices between consumers and pharmacies. The company was founded in 2015 and maintains its principal office in Santa Monica, California.
GDRX Revenue Breakdown
73.41% Prescription transactions
12.58% Subscription
11.34% Pharma manufacturer solutions
2.67% Other
GDRX Stock 12 Month Forecast
Average Price Target
$3.60
▲(58.59% Upside)
Technical Analysis
Ownership Overview
11.77% Insiders
11.57% Mutual Funds
9.75% Other Institutional Investors
57.31% Public Companies and
Individual Investors